{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:52:10Z","timestamp":1790218330182,"version":"4.1.0"},"reference-count":36,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Infect Immun"],"published-print":{"date-parts":[[2002,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Immunity against<jats:italic>Mycobacterium tuberculosis<\/jats:italic>depends largely on activation of cell-mediated responses, and gamma interferon has been shown to play a crucial role in this process in both humans and animal models. Since the lung is normally the organ in which infection is initiated and is the major site of pathology, immune responses in the lung play a significant role in restricting initial infection with<jats:italic>M. tuberculosis<\/jats:italic>. The aim of the present study was to stimulate efficient immunity in the lung by targeting the gut mucosa. Detoxified monophosphoryl lipid A (MPL) has been shown to be a relatively nontoxic adjuvant which efficiently promotes the induction of type 1 responses when it is given by the traditional subcutaneous route. We have therefore compared subcutaneous immunization of mice to oral immunization by using a model subunit vaccine carrying two immunodominant proteins from<jats:italic>M. tuberculosis<\/jats:italic>, in combination with MPL-based adjuvants. While less effective when used to prime a response, a heterologous priming and boosting vaccination strategy employing oral boosting induced significant systemic type 1 responses which equaled and surpassed those attained by subcutaneous immunization protocols. Moreover, the increased immune responses observed correlated with the induction of substantial protection against subsequent aerosol infection with virulent<jats:italic>M. tuberculosis<\/jats:italic>at levels comparable to, or better than, those obtained by multiple subcutaneous vaccinations. These results demonstrate that booster vaccinations via mucosal surfaces, by combining efficient subunit vaccines with the potent adjuvant MPL, may be an effective method of addressing some of the shortcomings of current vaccination strategies.<\/jats:p>","DOI":"10.1128\/iai.70.6.3111-3121.2002","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:09:29Z","timestamp":1027764569000},"page":"3111-3121","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":81,"title":["Oral Vaccination with Subunit Vaccines Protects Animals against Aerosol Infection with<i>Mycobacterium tuberculosis<\/i>"],"prefix":"10.1128","volume":"70","author":[{"given":"T. Mark","family":"Doherty","sequence":"first","affiliation":[{"name":"Department of Tuberculosis Immunology, Statens Serum Institute, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja Weinrich","family":"Olsen","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis Immunology, Statens Serum Institute, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurens","family":"van Pinxteren","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis Immunology, Statens Serum Institute, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis Immunology, Statens Serum Institute, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/90667"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.6.2536-2544.1994"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(01)01865-8"},{"key":"e_1_3_2_5_2","unstructured":"Anonymous. 2001. Global tuberculosis control. World Health Organization report W. H. O.\/CDS\/TB\/2001.287."},{"key":"e_1_3_2_6_2","first-page":"229","volume":"70","year":"1995","unstructured":"Anonymous. 1995. Global tuberculosis programme and global programme on vaccines: statement on BCG revaccination for the prevention of tuberculosis. Wkly. Epidemiol. Rec.70:229-236.","journal-title":"Wkly. Epidemiol. Rec."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.3.1605-1612.2001"},{"key":"e_1_3_2_8_2","first-page":"35","volume":"60","year":"1999","unstructured":"Boyaka, P. N., M. Marinaro, J. L. Vancott, I. Takahashi, K. Fujihashi, M. Yamamoto, F. W. van Ginkel, R. J. Jackson, H. Kiyono, and J. R. McGhee. 1999. Strategies for mucosal vaccine development. Am. J. Trop. Med. Hyg.60:35-45.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.68.2.791-795.2000"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.2.672-678.2002"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.96.1.29"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1999.tb01339.x"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Del Giudice G. A. Podda and R. Rappuoli. 2001. What are the limits of adjuvanticity? Vaccine 20: S38-S41.","DOI":"10.1016\/S0264-410X(01)00288-2"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2000.917304.x"},{"key":"e_1_3_2_15_2","unstructured":"Curr. Opin. Pulm. Res. 2002"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2001.056006498.x"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.9.4853"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92348-9"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Gheorghiu M. and P. H. Lagrange. 1983. Viability heat stability and immunogenicity of four BCG vaccines prepared from four different BCG strains. Ann. Immunol. (Paris) 134C: 125-147.","DOI":"10.1016\/S0769-2625(83)80157-3"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.2.1075"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.8.4518"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.6.863"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7274.1435"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.65.2.623-629.1997"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.2000.tb01444.x"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02730815"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.2.430-445.2001"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.5.2773-2778.2001"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0966-842X(00)01949-1"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.9.5067"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.4049\/jimmunol.156.10.3727","volume":"156","year":"1996","unstructured":"Rott, L. S., M. J. Briskin, D. P. Andrew, E. L. Berg, and E. C. Butcher. 1996. A fundamental subdivision of circulating lymphocytes defined by adhesion to mucosal addressin cell adhesion molecule-1. Comparison with vascular cell adhesion molecule-1 and correlation with beta 7 integrins and memory differentiation. J. Immunol.156:3727-3736.","journal-title":"J. Immunol."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni712"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/15058"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.74.2.144"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(97)00254-5"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2001.01265.x"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.7.3680-3685.1999"}],"container-title":["Infection and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.70.6.3111-3121.2002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.70.6.3111-3121.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T16:04:19Z","timestamp":1682265859000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/IAI.70.6.3111-3121.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["10.1128\/IAI.70.6.3111-3121.2002"],"URL":"https:\/\/doi.org\/10.1128\/iai.70.6.3111-3121.2002","relation":{},"ISSN":["0019-9567","1098-5522"],"issn-type":[{"value":"0019-9567","type":"print"},{"value":"1098-5522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6]]},"assertion":[{"value":"2002-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-03-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}